| Ytd | -24.83% | |
| 1y | -5.88% |
| Open | 1.13 | Prev Close | 1.15 | Low | 1.08 | High | 1.13 | Mkt Cap | 18.67M |
| Vol | 0.00 | Avg Vol | 58.71K | EPS | -0.61 | P/E | -1.84 | Forward P/E | -2.34 |
| Beta | 1.49 | Short Ratio | 1.55 | Inst. Own | 22.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.35 | 200-d Avg | 1.41 | 1yr Est | 19.00 |
MRKR News
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a
MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses,
After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pi
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may p
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractor
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T c
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Marker Therapeutics, Inc. MRKR on Tuesday provided an update on the progress and clinical observatio
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 6
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced a
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average vo
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company
On Friday, 93 stocks made new 52-week lows.
On Thursday, 175 stocks hit new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
On Friday, 497 companies set new 52-week lows.
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% o
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after ju
Gainers
Monday's session saw 84 companies set new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
Gainers
During Tuesday's trading, 505 companies set new 52-week lows.
On Friday, 313 companies hit new 52-week lows.
On Thursday, 147 companies achieved new lows for the year.
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss
During Friday's session, 445 companies made new 52-week lows.
Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for
Gainers Clovis Oncology, Inc. (NASDAQ: CLVS) shares climbed 47.7% to close at $7.86 on Friday af
Gainers Clovis Oncology, Inc. (NASDAQ: CLVS) shares jumped 44.8% to $7.70 after the company anno
Gainers
On Tuesday, 596 companies set new 52-week highs.
Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday af
Stocks That Hit 52-Week Lows On Monday